The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer - A prospective randomized multicenter trial with special focus on assessment of quality of life

被引:119
作者
Van Heek, NT
De Castro, SMM
van Eijck, CH
van Geenen, RCI
Hesselink, EJ
Breslau, PJ
Tran, TCK
Kazemier, G
Visser, MRM
Busch, ORC
Obertop, H
Gouma, DJ
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Psychol Med, NL-1105 AZ Amsterdam, Netherlands
[3] Onze Lieve Vrouw Hosp, Dept Surg, Amsterdam, Netherlands
[4] Univ Rotterdam, Hosp Dijkzigt, Rotterdam, Netherlands
[5] Hosp Gelre Apeldoorn, Apeldoorn, Netherlands
[6] Hosp Rode Kruis, The Hague, Netherlands
关键词
D O I
10.1097/01.sla.0000098617.21801.95
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To evaluate the effect of a prophylactic gastrojejunostomy on the development of gastric outlet obstruction and quality of life in patients with unresectable periampullary cancer found during explorative laparotomy. Summary Background Data: Several studies, including one randomized trial, propagate to perform a prophylactic gastrojejunostomy routinely in patients with periampullary cancer found to be unresectable during laparotomy. Others suggest an increase of postoperative complications. Controversy still exists in general surgical practice if a double bypass should be performed routinely in these patients. Methods: Between December 1998 and March 2002, patients with a periampullary carcinoma who were found to be unresectable during exploration were randomized to receive a double bypass (hepaticojejunostomy and a retrocolic gastrojejunostomy) or a single bypass (hepaticojejunostomy). Randomization was stratified for center and presence of metastases. Patients with gastrointestinal obstruction and patients treated endoscopically for more than 3 months were excluded. Primary endpoints were development of clinical gastric outlet obstruction and surgical intervention for gastric outlet obstruction. Secondary endpoints were mortality, morbidity, hospital stay, survival, and quality of life, measured prospectively by the EORTC-C30 and Pan26 questionnaires. It was decided to perform an interim analysis after inclusion of 50% of the patients (n = 70). Results: Five of the 70 patients randomized were lost to follow-up. From the remaining 65 patients, 36 patients underwent a double and 29 a single bypass. There were no differences in patient demographics, preoperative symptoms, and surgical findings between the groups. Clinical symptoms of gastric outlet obstruction were found in 2 of the 36 patients (5.5%) with a double bypass, and in 12 of the 29 patients (41.4%) with a single bypass (P = 0.001). In the double bypass group, one patient (2.8%) and in the single bypass group 6 patients (20.7%) required (re-)gastrojejunostomy during follow-up (P = 0.04). The absolute risk reduction for reoperation in the double bypass group was 18%, and the numbers needed to treat was 6. Postoperative morbidity rates, including delayed gastric emptying, were 31% in the double versus 28% in the single bypass group (P = 0.12). Median postoperative length of stay was 11 days (range 4-76 days) in the double versus 9 days (range 6-20 days) in the single bypass group (P = 0.06); median survival was 7.2 months in the double versus 8.4 months in the single bypass group (P = 0.15). No differences were found in the quality of life between both groups. After surgery most quality of life scores deteriorated temporarily and were restored to their baseline score (t = -1) within 4 months. Conclusions: Prophylactic gastrojejunostomy significantly decreases the incidence of gastric outlet obstruction without increasing complication rates. There were no differences in quality of life between the two groups. Together with the previous randomized trial from the Hopkins group, this study provides sufficient evidence to state that a double bypass consisting of a hepaticojejunostomy and a prophylactic gastrojejunostomy is preferable to a single bypass consisting of only a hepaticojejunostomy in patients undergoing surgical palliation for unresectable periampullary carcinoma. Therefore, the trial was stopped earlier than planned.
引用
收藏
页码:894 / 902
页数:9
相关论文
共 53 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   SELF-EXPANDABLE STAINLESS-STEEL ENDOPROSTHESES FOR TREATMENT OF MALIGNANT BILE-DUCT OBSTRUCTION [J].
ADAM, A ;
CHETTY, N ;
RODDIE, M ;
YEUNG, E ;
BENJAMIN, IS .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1991, 156 (02) :321-325
[3]  
[Anonymous], ANN SURG
[4]   PSYCHOMETRIC VALIDATION OF THE EORTC CORE QUALITY-OF-LIFE QUESTIONNAIRE, 30-ITEM VERSION AND A DIAGNOSIS-SPECIFIC MODULE FOR HEAD AND NECK-CANCER PATIENTS [J].
BJORDAL, K ;
KAASA, S .
ACTA ONCOLOGICA, 1992, 31 (03) :311-321
[5]  
Blazeby J M, 2001, Expert Rev Anticancer Ther, V1, P269, DOI 10.1586/14737140.1.2.269
[6]   Quality of life evaluation in oncological clinical trials - the EORTC model [J].
de Haes, J ;
Curran, D ;
Young, T ;
Bottomley, A ;
Flechtner, H ;
Aaronson, N ;
Blazeby, J ;
Bjordal, K ;
Brandberg, Y ;
Greimel, E ;
Maher, J ;
Sprangers, M ;
Cull, A .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (07) :821-825
[7]   EVALUATION OF PALLIATIVE SURGICAL-PROCEDURES IN UNRESECTABLE PANCREATIC-CANCER [J].
DEROOIJ, PD ;
ROGATKO, A ;
BRENNAN, MF .
BRITISH JOURNAL OF SURGERY, 1991, 78 (09) :1053-1058
[8]  
EGRARI S, 1995, AM SURGEON, V61, P862
[9]  
*EORTC, 2001, EORTC QLQ C30 MAN
[10]   Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer [J].
Fitzsimmons, D ;
Johnson, CD ;
George, S ;
Payne, S ;
Sandberg, AA ;
Bassi, C ;
Beger, HG ;
Birk, D ;
Büchler, MW ;
Dervenis, C ;
Cruz, LF ;
Friess, H ;
Grahm, AL ;
Jeekel, J ;
Laugier, R ;
Meyer, D ;
Singer, MW ;
Tihanyi, T .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (06) :939-941